0.7901
price up icon0.64%   0.005
after-market Dopo l'orario di chiusura: .79 -0.000100 -0.01%
loading

Cue Biopharma Inc Borsa (CUE) Ultime notizie

pulisher
Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Cue Biopharma stock holds $2 target, Market Outperform rating By Investing.com - Investing.com South Africa

Apr 21, 2025
pulisher
Apr 17, 2025

Petri Dish: Roche unloads drug to Cambridge biotech, Cue and Boehringer link up - The Business Journals

Apr 17, 2025
pulisher
Apr 16, 2025

Cue Biopharma stock falls after pricing capital raise of $20M via securities offering - MSN

Apr 16, 2025
pulisher
Apr 16, 2025

Cue Biopharma Inc Announces $20 Million Public Offering Amidst C - GuruFocus

Apr 16, 2025
pulisher
Apr 16, 2025

Boehringer and Cue Biopharma to develop autoimmune therapies - Pharmaceutical Technology

Apr 16, 2025
pulisher
Apr 16, 2025

Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune,... - Medical Dialogues

Apr 16, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Partners with Boehringer Ingelheim to Advance B Cell Therapy | CUE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer’s bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M - Endpoints News

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Rises On Partnership With Boehringer To Develop CUE-501 For Autoimmune Diseases - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases - Contract Pharma

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma agree to advance CUE-501 for autoimmune diseases - BioWorld MedTech

Apr 15, 2025
pulisher
Apr 15, 2025

Cue stock in focus after pact with Boehringer (CUE:NASDAQ) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases - Lelezard

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer and Cue Biopharma partner to develop next-generation treatments - The Pharma Letter

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma stock holds $2 target, JMP reiterates rating - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Launches Public Offering of Common Stock and Warrants | CUE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma to Host Business Update Call and Webcast | CUE Sto - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Prices $20 Million Public Offering of Stock, Warrants - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop next-g - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Announces Proposed Public Offering | CUE Stock New - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma (CUE) Stock Dips Amid $20M Public Offering Announcement - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Cue Biopharma Prices About $20 Mln Public Offering - Nasdaq

Apr 15, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Pub - GuruFocus

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789 - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

$20M Capital Raise: Inside Cue Biopharma's Latest Strategic Financing Move - Stock Titan

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma launches public stock offering By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma inks deal with Boehringer Ingelheim By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer, Cue Biopharma ink autoimmune therapy deal By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma launches public stock offering - Investing.com Australia

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma inks deal with Boehringer Ingelheim - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer, Cue Biopharma ink autoimmune therapy deal - Investing.com

Apr 14, 2025
pulisher
Apr 14, 2025

Form 424B5 Cue Biopharma, Inc. - StreetInsider

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma to Host Business Update Call and Webcast - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

Cue Biopharma Announces Proposed Public Offering - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

Boehringer Ingelheim and Cue Biopharma partner to develop - GlobeNewswire

Apr 14, 2025
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
Capitalizzazione:     |  Volume (24 ore):